Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to Release Quarterly Earnings on Wednesday
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is set to issue its quarterly earnings data before the market opens on Wednesday, August 2nd. Analysts expect the company to announce earnings of ($1.21) per share for the quarter.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by $0.03. Alnylam Pharmaceuticals had a negative net margin of 705.11% and a negative return on equity of 42.90%. The business had revenue of $19 million during the quarter, compared to analysts’ expectations of $22.91 million. During the same period last year, the company posted ($1.21) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 160.3% on a year-over-year basis. On average, analysts expect Alnylam Pharmaceuticals to post $-5.23 EPS for the current fiscal year and $-4.94 EPS for the next fiscal year.
Shares of Alnylam Pharmaceuticals, Inc. (ALNY) opened at 81.01 on Wednesday. The stock has a 50 day moving average of $78.83 and a 200-day moving average of $58.26. The stock’s market cap is $6.98 billion. Alnylam Pharmaceuticals, Inc. has a 52 week low of $31.38 and a 52 week high of $86.92.
TRADEMARK VIOLATION WARNING: “Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to Release Quarterly Earnings on Wednesday” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/26/alnylam-pharmaceuticals-inc-nasdaqalny-to-release-quarterly-earnings-on-wednesday.html.
In other news, major shareholder Sanofi bought 297,501 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, May 31st. The stock was acquired at an average cost of $71.87 per share, for a total transaction of $21,381,396.87. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Akshay Vaishnaw sold 43,750 shares of the business’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $65.00, for a total transaction of $2,843,750.00. Following the completion of the transaction, the senior vice president now owns 43,047 shares of the company’s stock, valued at $2,798,055. The disclosure for this sale can be found here. Insiders sold 64,125 shares of company stock valued at $4,325,000 over the last quarter. 4.30% of the stock is currently owned by corporate insiders.
A number of analysts have recently issued reports on the stock. Jefferies Group LLC reissued a “buy” rating and set a $102.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, June 22nd. Chardan Capital reissued a “buy” rating and set a $131.00 target price (up from $110.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, July 10th. Needham & Company LLC reissued a “buy” rating and set a $98.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, July 10th. J P Morgan Chase & Co reissued a “hold” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, June 26th. Finally, Credit Suisse Group boosted their target price on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the company an “outperform” rating in a research note on Tuesday, June 27th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company’s stock. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $78.83.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.